Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic prediction in the wild: A case study in Soay sheep.
Ashraf B, Hunter DC, Bérénos C, Ellis PA, Johnston SE, Pilkington JG, Pemberton JM, Slate J. Ashraf B, et al. Among authors: ellis pa. Mol Ecol. 2022 Dec;31(24):6541-6555. doi: 10.1111/mec.16262. Epub 2021 Nov 10. Mol Ecol. 2022. PMID: 34719074 Free article.
Inbreeding depression across the lifespan in a wild mammal population.
Huisman J, Kruuk LE, Ellis PA, Clutton-Brock T, Pemberton JM. Huisman J, et al. Among authors: ellis pa. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3585-90. doi: 10.1073/pnas.1518046113. Epub 2016 Mar 15. Proc Natl Acad Sci U S A. 2016. PMID: 26979959 Free PMC article.
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS, Stone JD, Konieczna I, Calabrese KM, Wang N, Haribhai D, Dong F, White MK, Rodriguez LE, Bukofzer GT, Ellis PA, Cosgrove C, Hecquet C, Clarin JD, Palma JP, Reilly EB. Chervin AS, et al. Among authors: ellis pa. Mol Cancer Ther. 2023 Aug 1;22(8):903-912. doi: 10.1158/1535-7163.MCT-22-0770. Mol Cancer Ther. 2023. PMID: 37294945
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Krop IE, et al. Among authors: ellis pa. J Clin Oncol. 2022 Feb 10;40(5):438-448. doi: 10.1200/JCO.21.00896. Epub 2021 Dec 10. J Clin Oncol. 2022. PMID: 34890214 Free PMC article. Clinical Trial.
90 results